Distinguished in Essential Thrombocythemia

Zhijian J. Xiao

Tianjin, CN 
Distinguished in Essential Thrombocythemia
Tianjin, CN 
OverviewLocationsClinical Research

Overview

Zhijian Xiao practices in Tianjin, China. Xiao is rated as a Distinguished expert by MediFind in the treatment of Essential Thrombocythemia. Their top areas of expertise are Myelodysplastic Syndrome (MDS), Polycythemia Vera, Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 264 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 11 articles in the study of Essential Thrombocythemia.

Locations

Tianjin, China
Other Locations
Guangdong Key Laboratory Of Environmental Pollution And Health, Guangzhou, 511443, China
No. 288, Nanjing Road, Xiaobailou, 300020, China
China
Beijing, 100084, China
Fujian Provincial Key Laboratory Of Innovative Drug Target Research, Xiamen, 361102, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 3
A Phase I/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) Patients After Failure of Hypomethylating Agent (HMA)-Based Therapy
A Phase I/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) Patients After Failure of Hypomethylating Agent (HMA)-Based Therapy
Enrollment Status: Terminated
Publish Date: April 17, 2024
Intervention Type: Drug
Study Drug: ATG-016
Study Phase: Phase 1/Phase 2
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

264 Total Publications

Construction and assessment of a predictive framework for Enterobacterales bloodstream infection in real-world adult onco-hematology patients using Lasso-Cox regression.
Construction and assessment of a predictive framework for Enterobacterales bloodstream infection in real-world adult onco-hematology patients using Lasso-Cox regression.
Journal: Antimicrobial agents and chemotherapy
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xiao's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile